Cambiar Investors LLC Sells 1,286 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Cambiar Investors LLC decreased its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 0.7% in the third quarter, Holdings Channel.com reports. The firm owned 188,745 shares of the company’s stock after selling 1,286 shares during the period. Cambiar Investors LLC’s holdings in HealthEquity were worth $15,449,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in HQY. Motley Fool Asset Management LLC lifted its position in HealthEquity by 3,001.0% in the first quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock valued at $307,097,000 after purchasing an additional 3,640,748 shares during the last quarter. Mackenzie Financial Corp raised its holdings in HealthEquity by 16.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after buying an additional 325,906 shares during the last quarter. Generate Investment Management Ltd purchased a new stake in HealthEquity during the 2nd quarter valued at $24,184,000. Thrivent Financial for Lutherans grew its holdings in HealthEquity by 924.2% in the 2nd quarter. Thrivent Financial for Lutherans now owns 220,220 shares of the company’s stock worth $18,983,000 after acquiring an additional 198,718 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of HealthEquity by 1.7% during the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after acquiring an additional 149,133 shares during the last quarter. Institutional investors own 99.55% of the company’s stock.

Insider Activity at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the sale, the director now directly owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Frank Corvino sold 1,247 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the transaction, the director now directly owns 4,823 shares in the company, valued at $387,093.98. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the company’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the transaction, the director now directly owns 54,719 shares in the company, valued at $4,540,582.62. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on HQY shares. Bank of America cut their target price on HealthEquity from $105.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Barrington Research reissued an “outperform” rating and set a $105.00 target price on shares of HealthEquity in a research note on Friday, September 20th. JMP Securities restated a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $92.00 price objective on shares of HealthEquity in a report on Wednesday, September 4th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $103.83.

HealthEquity Stock Up 1.3 %

Shares of HealthEquity stock opened at $86.33 on Friday. HealthEquity, Inc. has a 1 year low of $61.81 and a 1 year high of $89.23. The firm has a market cap of $7.54 billion, a price-to-earnings ratio of 71.94, a PEG ratio of 1.35 and a beta of 0.52. The company has a 50-day moving average of $81.24 and a 200 day moving average of $79.92. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The business had revenue of $299.93 million for the quarter, compared to analysts’ expectations of $284.48 million. As a group, sell-side analysts anticipate that HealthEquity, Inc. will post 2.27 earnings per share for the current fiscal year.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.